Zobrazeno 1 - 10
of 91
pro vyhledávání: '"D. Tsavdaridis"'
Autor:
Shanmuganathan Gunalan, Eleni Iacovidou, Brabha Nagaratnam, Konstantinos D. Tsavdaridis, Keerthan Poologanathan, Gatheeshgar Perampalam
Publikováno v:
ce/papers. 3:219-224
The use of modular building systems (MBSs) in the construction sector is increasing. MBSs enhance structural performance of buildings, quality control, and construction speed than traditional methods at a lower cost. Additional benefits can be associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d15b1dd18ba2f8e61ba162b2782ed76f
https://doi.org/10.1002/cepa.1160
https://doi.org/10.1002/cepa.1160
Autor:
D. Tsavdaridis, Papadimitriou Ca, P. Makrantonakis, A. Polychronis, Pavlos Papakostas, C. Christodoulou, E. Razis, Helen Gogas, D.V. Skarlos, A. M. Dimopoulos, P. Kosmidis, Eleni Timotheadou, H. P. Kalofonos, Evangelos Briasoulis, Dimitris Bafaloukos, Urania Dafni, George Fountzilas, Christos Markopoulos, Dimitrios Pectasides, Vassiliki Siafaka, Gerassimos Aravantinos
Publikováno v:
Annals of Oncology. 16:1762-1771
Purpose: The aim of this study was to explore the effect of dose-dense sequential chemotherapy with or without paclitaxel primarily on disease-free survival (DFS) and secondarily on overall survival (OS) in patients with high-risk operable breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ef6f8f611afa255beeb0ddc866812f
https://doi.org/10.1093/annonc/mdi366
https://doi.org/10.1093/annonc/mdi366
Autor:
D. Tsavdaridis, J. Stathopoulos, George P. Stathopoulos, P. Michalopoulou, J. Dimitroulis, C. Katis, D. Antoniou, C. Marosis, O. Armenaki, T. Grigoratou
Publikováno v:
British Journal of Cancer
Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In total, 56 patients with inoperable or meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218329364acf8cf4a096e48e120ad3ed
https://doi.org/10.1038/sj.bjc.6602827
https://doi.org/10.1038/sj.bjc.6602827
Autor:
N. Pergantas, George P. Stathopoulos, J. Stathopoulos, Ch. Kosmas, D. Tsavdaridis, S. K. Rigatos, N. A. Malamos, J. Xynotroulas
Publikováno v:
Cancer Chemotherapy and Pharmacology. 56:487-491
Purpose: This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively. Methods: Forty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b1648ea46f6908b8caef4ce2a7039e
https://doi.org/10.1007/s00280-005-1006-3
https://doi.org/10.1007/s00280-005-1006-3
Autor:
Evangelia Razis, Pavlos Papakostas, Christos Christodoulou, Haralambos P. Kalofonos, George Fountzilas, Maria Karina, Helen Gogas, Gerassimos Aravantinos, Dimosthenis Skarlos, Anna Kalogera-Fountzila, D. Tsavdaridis
Publikováno v:
Cancer Investigation. 22:655-662
Advanced breast cancer (ABC) is an incurable disease. Standard first-line treatment for patients with HER-2/neu overexpressing tumors includes the combination of the humanized monoclonal antibody trastuzumab with chemotherapy, mainly paclitaxel. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a04712e2a40fd47762899ca65f677f98
https://doi.org/10.1081/cnv-200032980
https://doi.org/10.1081/cnv-200032980
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer
Autor:
E. Razis, D.V. Skarlos, Eleni Timotheadou, George P. Stathopoulos, Anna Kalogera-Fountzila, Adamos Adamou, Pavlos Papakostas, P. Kosmidis, C. Christodoulou, Helen Gogas, G. Fountzilas, D. Tsavdaridis, Dimitris Bafaloukos, C H Kalofonos
Publikováno v:
Annals of Oncology. 12:1545-1551
Summary Aim to evaluate the activity and acute toxicity of the combination of weekly paclitaxel as first-line chemotherapy and trastuzumab, in patients with HER-2/neu overexpressing advanced breast cancer (ABC) Background Weekly paclitaxel has been s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5665e0e86256bec2023ffd1d38a81ff2
https://doi.org/10.1023/a:1013184301155
https://doi.org/10.1023/a:1013184301155
Autor:
D. Karaindros, George P. Stathopoulos, J. Dimitroulis, J. Stathopoulos, D. Tsavdaridis, C. Katis, E. Dimou
Publikováno v:
Cancer chemotherapy and pharmacology. 58(4)
Purpose: Based on previous experience, we combined topotecan with paclitaxel (weekly administration) in patients with non-small-cell lung cancer (NSCLC). Our primary objective was to determine the response rate and survival and our secondary objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc37391051717e17509fed1670766b7
https://pubmed.ncbi.nlm.nih.gov/16520987
https://pubmed.ncbi.nlm.nih.gov/16520987
Autor:
Athanassios Sakantamis, George Fountzilas, Dimitrios Bafaloukos, D. Tsavdaridis, Dimosthenis Skarlos, N. Xiros, Aristotelis Bamias, Pavlos Papakostas, Dimitrios Janinis, Paris Kosmidis, Haralabos P. Kalofonos
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 9(1)
We assessed the efficacy and safety profile of a docetaxel (Taxotere; Sanofi-Aventis, France), fluorouracil (FU), and leucovorin (LV) combination (TFL), as first-line chemotherapy in patients with advanced gastric cancer.Fifty-eight patients with adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49ade0a18c71e06bfedc0cfe86383cb5
https://pubmed.ncbi.nlm.nih.gov/16557433
https://pubmed.ncbi.nlm.nih.gov/16557433
Autor:
N. Maniadakis, D. Tsavdaridis, Vassiliki Siafaka, Papadimitriou Ca, P. Makrantonakis, George Fountzilas, Dimitris Bafaloukos, H. P. Kalofonos, Lia A. Moulopoulos, Meletios A. Dimopoulos, Pavlos Papakostas, T. Economopoulos, Gerassimos Aravantinos, C. Christodoulou, Helen Gogas, E. Razis, D.V. Skarlos, Anna Kalogera-Fountzila, D.G. Pectasides, Urania Dafni, Evangelos Briasoulis, P. Kosmidis
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(10)
Background To compare survival between patients with advanced breast cancer (ABC) treated with epirubicin/paclitaxel (Taxol) or paclitaxel/carboplatin (Cp) chemotherapy. Patients and methods From January 1999 to April 2002, 327 eligible patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79031f2b76ed55da9e306602327312a9
https://pubmed.ncbi.nlm.nih.gov/15367413
https://pubmed.ncbi.nlm.nih.gov/15367413
Autor:
S. K. Rigatos, N. Georgatou, E. Kalatzi, K. Marossis, George P. Stathopoulos, T. Grigoratou, A. Paspalli, M. Charalambatou, A. Gerogianni, P. Michalopoulou, M. Veslemes, D. Antoniou, S. Loukides, I. Dimitroulis, P. Giamboudakis, K. Vergos, K. Katis, S. Bastani, D. Tsavdaridis, M. Stoka
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(7)
Purpose: This randomized phase III trial of advanced or metastatic non-small-cell lung cancer (NSCLC) was designed to compare a standard treatment such as carboplatin (CRP)– paclitaxel (PCT) with a new combination, vinorelbine (VRL)– PCT—two ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106b739cd57f8b3b26ed4481942c255c
https://pubmed.ncbi.nlm.nih.gov/15205198
https://pubmed.ncbi.nlm.nih.gov/15205198